Tumour budding is associated with the mesenchymal colon cancer subtype and RAS/RAF mutations: a study of 1320 colorectal cancers with Consensus Molecular Subgroup (CMS) data
Open Access
- 2 November 2018
- journal article
- research article
- Published by Springer Nature in British Journal of Cancer
- Vol. 119 (10) , 1244-1251
Abstract
Tumour budding is an important prognostic factor in colorectal cancer (CRC). Molecular profiling of tumour buds suggests (partial) epithelial–mesenchymal transition and cancer stem-cell phenotype, similarly described in the “mesenchymal” Consensus Molecular Subtype 4 (CMS4), which identifies a particularly poor prognostic subgroup. Here, we determine the association of tumour budding with CMS classification, prognosis, and response to therapy. AMC-AJCCII-90 cohort (n = 76, stage II) was evaluated for peritumoural budding on H&E slides. LUMC (n = 270, stage I–IV), CAIRO (n = 504, metastatic CRC) and CAIRO2 (n = 472, metastatic CRC) cohorts were investigated for intratumoural budding using pan-cytokeratin-stained tissue microarrays. Budding was scored as count/area, then classified as p = 0.018), LUMC (p < 0.0001), and CAIRO (p = 0.03), and in CAIRO2 (continuous variable, p = 0.02). Tumour budding counts were higher in CMS4 compared to epithelial CMS2/3 cancers (p < 0.01, all), and associated with KRAS/BRAF mutations (p < 0.01, AMC-AJCCII-90, CAIRO, CAIRO2). Tumour budding is an adverse prognostic factor across all CRC stages and is associated with the mesenchymal CMS4 phenotype. KRAS/BRAF mutations are strongly correlated with tumour budding suggesting their involvement in the regulation of this process.Keywords
This publication has 31 references indexed in Scilit:
- Prognostic Impact of Tumor-Budding Grade in Stages 1–3 Colon Cancer: A Retrospective Cohort StudyAnnals of Surgical Oncology, 2017
- MicroRNA-200b is downregulated in colon cancer budding cellsPLOS ONE, 2017
- Systematic review and meta-analysis of the impact of tumour budding in colorectal cancerBritish Journal of Cancer, 2016
- Tumor Budding: The Name is EMT. Partial EMT.Journal of Clinical Medicine, 2016
- The consensus molecular subtypes of colorectal cancerNature Medicine, 2015
- High Prevalence and Clinical Relevance of Genes Affected by Chromosomal Breaks in Colorectal CancerPLOS ONE, 2015
- Mismatch Repair Status and BRAF Mutation Status in Metastatic Colorectal Cancer Patients: A Pooled Analysis of the CAIRO, CAIRO2, COIN, and FOCUS StudiesClinical Cancer Research, 2014
- Intratumoral budding as a potential parameter of tumor progression in mismatch repair–proficient and mismatch repair–deficient colorectal cancer patientsHuman Pathology, 2011
- Tumor budding predicts response to anti-EGFR therapies in metastatic colorectal cancer patientsWorld Journal of Gastroenterology, 2010
- Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trialThe Lancet, 2007